

Figure S1. Principle coordinates analysis plots comparing bacterial community structure between faeces, colonic scrapings, colonic contents and caecal contents at week 8 based on Spearman distances. (a) Samples from conventional mice cross over design. (b) Samples from germ-free mice cross over design. The significant differences between groups were calculated by analysis of similarity (ANOSIM) tests. Abbreviations: CM, Community; LS, Long-stay; W8, week 8 (feaces); ColS, colonic scraping; ColC, colonic content; CaeC, caecal content.



Figure S2a.



Figure S2. Gut microbiota composition at the genus level of conventional mice inoculated with a community microbiota (**a**) or with a long-stay microbiota (**b**), grouped by time points. *P*-values were calculated using Wilcoxon signed-rank tests and were corrected for the multiple comparison using the Benjamini–Hochberg adjustment, *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: CM donor, healthy community subject; LS donor, frail long-stay subject; and Week -7 (week minus 7), murine microbiota before antibiotic treatment.



Figure S3a.



Figure S3. Gut microbiota composition at the genus level of germ-free mice inoculated with a community microbiota (**a**) or with a long-stay microbiota (**b**), grouped by time points. *P*-values were calculated using Wilcoxon signed-rank tests and were corrected for the multiple comparison using the Benjamini–Hochberg adjustment, *p < 0.05, **p < 0.01, ***p < 0.001. Abbreviations: CM donor, healthy community subject; LS donor, frail long-stay subject.



Figure S4. Alpha diversity comparisons of the human gut microbiome at baseline (T0),

grouped by residence location (a) or residence location and treatment group (b). *P*-values were calculated using Kruskal-Wallis test for three independent groups and Mann-Whitney U tests for unpaired groups, ***p < 0.001.



Figure S5. Beta diversity comparisons based on Bray-Curtis distances of the human gut microbiome at baseline (T0), grouped by residence location (a) or residence location and treatment group (b). The significant differences between groups were calculated by ANOSIM tests. Abbreviations: Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay.



Figure S6. Boxplot of bacterial alpha-diversity indices for the 16S rRNA gene sequences between different time points in each treatment groups. *P*-values were calculated from linear mixed effects models. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay; T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).



Figure S7. Principle Coordinates Analysis based on Bray-Curtis distances of partial sequences of bacterial 16S rRNA genes from human faecal samples of treatment groups, grouped by time points. The significant differences between groups were calculated by ANOSIM tests. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay; T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).



Figure S8. Relative abundance of faecal microbiota taxa at (**a**) phylum level, (**b**) family level in subjects, grouped according to treatment groups and time points. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay; T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).



Firmicutes.Clostridia.Clostridiales.Ruminococcaceae

Firmicutes.Clostridia.Clostridiales.Ruminococcaceae.Clostridium IV







YH intervention YH placebo Relative abundance (%) L 0 то то T26 T32 T13 T26 T32 T13





Firmicutes.Negativicutes.Selenomonadales.Acidaminococcaceae.Phascolarctobacterium







Figure S9.





Supplementar Figure S9. Box plot of relative abundances of the statistically significantly different taxa after treatment. Adjusted *p*-values were calculated by DESeq2 tests with Benjamini–Hochberg correction, *p < 0.05. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay; T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).

Placebo treatment YH placebo EC placebo LS placebo All placebo samples combined Anaerostipes F ŧ Dorea Ē Blautia unclassified Ruminococcaceae Pseudomonas Methanobrevibacter Achromobacter -4 0 Log2 Fold Change <u>.</u> <u>.</u>'2 -4 ż -<u>'</u>4 -2 0 Log2 Fold Change -12 -8 0 Log2 Fold Change 0 Log2 Fold Change Intervention treatment YH intervention EC intervention LS intervention All intervention samples combined Achromobacter Parabacteroides Clostridium IV Alistipes Anaerostipes Ruminococcus2 unclassified Lachnospiraceae Coprococcus Clostridium XIVa unclassified Peptostreptococcaceae

T32|T0

p.adjust - n.s

- 0.05 < p < 0.1

ż

ż

-2 0 Log2 Fold Change **→** p < 0.05

ż

ż

1 0 Log2 Fold Change ż

Pair comparison • T13|T0

Clostridium sensu stricto

-2 0 2 Log2 Fold Change ▲ T26|T0

Figure S10. Genera that were significantly increased (log2 fold change > 0) or decrease (log2 fold change < 0) in the placebo/prebiotic intervention to baseline at T0 across all available intervention or placebo samples, compared with the results from the individual cohorts. Adjusted *p*-values were calculated by DESeq2 test with Benjamini–Hochberg correction. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay. T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).

ż

ż

0 Log2 Fold Change



Figure S11.



Figure S11. Immunological/inflammatory profiling between time points within treatment groups. *P*-values were calculated from Wilcoxon signed-rank tests, *p < 0.05. Abbreviations: YH, Young-healthy; CM, Community; LS, Long-stay; T0, baseline (week 0); T13, halfway (week 13); T26, end of study (week 26); and T32, six weeks after the cessation of treatment (week 32).